~The Initiative CERVIVOUR aims to vaccinate 500,000 females by 2030~

May 22, 2025, New Delhi:  The commitment of raising awareness and eradicating cervical cancer, Aahwahan Foundation has started an initiative, “Protecting Women, Preventing Cervical Cancer“, aimed at empowering women against the battle of cervical cancer. According to a research conducted by India Human Papillomavirus (HPV) and Related Cancers in 2021, every year 1,23,907 women are diagnosed with cervical cancer and 77,348 die from the disease. The situation of women and children in rural areas and the underprivileged section of society, remains most affected due to lack of proper treatment, facilities, financial aid, etc.  Through this initiative, the foundation provides free HPV vaccinations to thousands of women and children in rural and financially disadvantaged communities who face barriers to accessing healthcare facilities. It is not just a vaccination drive; it is a symbol of empowerment, a statement that every individual, regardless of their background, deserves access to life-saving healthcare.

Aahwahan Foundation has come forward to address the need to provide HPV (Human Papillomavirus) vaccination to the underprivileged. The vaccination, priced at Rs.12, 000 approx. is being provided free of charge by the organization to young girls in schools and colleges. Over 17,650 individuals have received the vaccine so far. The Initiative CERVIVOUR aims to vaccinate 500,000 females by 2030, with significant progress already made in Haryana, Karnataka, Maharashtra, Uttar Pradesh, and Kerala. Through collaboration with the government and medical experts, the program conducts baseline studies, identifies target schools and colleges, raises awareness through group counselling sessions, and implements tailored projects, followed by continuous monitoring and follow-up to ensure sustained impact.

The foundation strives to empower women with the knowledge and resources needed to prevent cervical cancer, improve early detection rates, which ultimately save lives. The initiative fosters a supportive environment for women to discuss concern related to reproductive health concerns and encourages proactive health management within communities. The team also educates women about essential information of cervical cancer, its causes and risks through regular screenings, such as Pap tests and HPV vaccinations.

Ragini, a beneficiary of the initiative, said, “I never knew about cervical cancer or the vaccine until the camp came to our village. When the doctors explained how this simple injection could protect my daughters from a dangerous disease, I felt a sense of relief and hope. We could never afford such a vaccine, but this initiative gave it to us for free. My daughters now have a future where they can be healthy and strong, and as a mother, that means everything to me.”

“Our target to vaccinate 90% of eligible girls and women in the state by 2030, focusing on underserved and high-risk communities. “We are actively engaging with the ground level, covering rural and urban locations in Karnataka, and strategizing outreach programs to ensure a smooth rollout in the coming months. We are carrying out extensive awareness campaigns in different parts of these states, and we are looking forward to meeting a target of 10,000 girls & women in the initial phase of this project and 1,00,000 from each of the states soon.” said Mr. Braja Kishore Pradhan, CEO, Social Activist and Founder of the Aahwahan Foundation.

Through this project, Aahwahan Foundation is actively working towards creating a new India where cervical cancer is eliminated. They are committed to empowering women with knowledge and resources to prevent this disease, ensuring that no woman has to struggle with its devastating effects. By fostering awareness and promoting regular health screenings, they aim to build a supportive community where women can thrive, free from the fear of cervical cancer.

May 15, 2025: Hansa Research, India’s leading consumer insights firm, has released the 1st edition of Health Insurance Customer Experience Score (CuES) 2025 report. This comprehensive study offers a deep dive into the evolving preferences, expectations, and satisfaction levels of health insurance customers across the country, drawing insights from over 3,800 respondents across 12 health insurance brands, and presents a robust framework for insurers to sharpen their strategies and drive stronger customer engagement.

India’s health insurance sector, which saw a surge in adoption during the pandemic, continues to expand since then, (albeit at a moderated pace), as consumers prioritize financial protection amidst rising medical costs. According to the report, nearly half (48%) of health insurance buyers cited ‘protection from rising healthcare expenses’ as the primary driver for purchasing insurance, reflecting heightened concern over medical inflation. Moreover, customers increasingly view health insurance not just as a financial product, but as a gateway to access quality healthcare and better health outcomes. We are also seeing that nearly 30% of Policyholders supplement existing corporate health coverage with additional policies.

As the health insurance landscape in India becomes increasingly competitive — with a mix of public sector giants, private insurers, and standalone health firms, understanding and improving customer experience is no longer optional.

The Health Insurance CuES 2025 report pegs the Industry Net Promoter Score at 55% and among the top-ranked brands, Bajaj Allianz General Insurance, SBI General Insurance, and ICICI Lombard General Insurance emerge as standout performers. These brands are not only perceived as ‘trustworthy’ but also excel on product related aspects, ease of claim filing, hospital network access and customer support responsiveness among other things.

Among these, Bajaj Allianz General Insurance is leading the rankings with an impressive Net Promoter Score (NPS) of 68%, winning customer loyalty through strong product delivery, digital support, excellent claims experience, and a well-rated hospital network. The brand has successfully positioned itself as a customer-centric insurer, fostering high levels of satisfaction and loyalty.

Sharing some insights on the Hansa Research, Health Insurance CuES report, Praveen Nijhara, CEO, Hansa Research said, “The Health Insurance CuES 2025 report is a timely benchmark for the industry. It reflects a major shift in consumer mindset. Customers today are informed, vocal and expect seamless experiences and this highlights the importance of transparency, service quality and innovation in building lasting trust.”

Key Findings from the Health Insurance CuES 2025 Report

Evolving Customer Expectations
Customer expectations are rapidly changing, driven by a digital-first mindset for policy purchase and management. There is a clear preference for personalized, flexible, and wellness-oriented plans, which are associated with higher satisfaction and stronger brand affinity. Insurers that align offerings with these preferences are more likely to attract and retain today’s informed and health-conscious consumers.

Consumers’ brand preferences for health insurance

Consumers’ preferences for health insurance brands are shaped by three core factors: the product offering—particularly the range and coverage of critical illnesses and plan flexibility; a strong and trustworthy brand reputation; and convenient access to 24/7 customer service. Notably, younger millennials place greater emphasis on round-the-clock support and seamless digital experiences, making these critical differentiators for insurers targeting this demographic.

Portability Empowers Consumers

The growing ease of health insurance portability has shifted the balance of power toward the consumer, pushing insurers to focus on delivering value across the entire policyholder journey—not just at the point of acquisition. Increased competition is driving accountability. The study finds that premium increases, lack of transparency, and unsatisfactory claim experiences are the top reasons consumers switch providers. This highlights a growing demand for fair, transparent, and consistent service.

Claims Experience Remains a Key Challenge

The claims process continues to be a critical friction point, with 55% of claimants reporting difficulties. Key concerns include limited hospital networks, pre-authorization delays, and slow payouts. These issues are even more pronounced among millennials, who have higher expectations for speed and simplicity. A smooth and efficient cashless claims process is strongly linked to overall satisfaction, underlining the need for insurers to invest in both digital capabilities and operational efficiency.

Barriers Among Non-Policyholders

Despite rising awareness, several barriers continue to prevent non-policyholders from entering the health insurance ecosystem. The most cited concerns include a lack of perceived need/ benefits of health insurance, affordability, and complexity of terms and conditions. Addressing these barriers through clear communication, affordable micro-products, and simplified onboarding processes will be essential for expanding coverage and inclusion across demographics.

Piyali Chatterjee, Executive Vice President, CX, Hansa Research said, “Expansion of network coverage, simplifying pre-authorization protocols, and ensure timely settlements will improve customer trust. Addressing these issues is critical for strengthening India’s healthcare financing ecosystem and delivering a seamless insurance experience.

Mumbai, 15 May, 2025: MediBuddy, India’s leading digital healthcare company, has announced the appointment of Sidhartha Mehra as Chief Financial Officer (CFO). With over 20 years of global and Indian experience across multinational corporations and high-growth enterprises, Sidhartha has led Finance, Legal, Compliance, HR, Investments, and Procurement functions. He brings a rare blend of financial acumen and cross-functional leadership, with expertise in IPO, M&A, and strategic financial management.

In his role at MediBuddy, Sidhartha will lead MediBuddy’s financial strategy, capital management, and regulatory compliance. His proven expertise in managing large-scale M&A, corporate restructuring, finance transformation, and strategic capital allocation will be instrumental in driving long-term value creation for the company and its stakeholders.

Satish Kannan, Co-founder and CEO of MediBuddy, said, “Sidhartha’s strategic foresight, combined with his cross-functional expertise, makes him the ideal partner to help MediBuddy navigate its next phase of growth. His ability to align financial performance with broader business strategy will be key in building a financially resilient organisation that can scale sustainably.”

Commenting on his new role, Sidhartha Mehra, CFO, MediBuddy, said, “I’m thrilled to join MediBuddy as it accelerates its mission to make high quality healthcare accessible to all. Aligned with this vision, my focus will be on building a world-class finance function that enables scale, drives strategic growth, and unlocks long-term enterprise value. I look forward to driving measurable impact at scale—both within the business and across the communities we serve. It is deeply fulfilling to be associated with a purpose-driven company that is transforming lives through empathetic and tech-led healthcare.”

Sidhartha has held senior leadership positions across global financial institutions and leading Indian companies. Most recently, he served as the CFO and CHRO at Zolo, where he played a pivotal role in leading enterprise-wide transformation, driving operational efficiency and governance frameworks. Prior to this, he held leadership roles at Jupiter Capital, GE Capital, and Barclays, managing financial planning, regulatory compliance, and business analytics across global markets including the UK, Ireland, Belgium, and India.

In addition to his corporate leadership, Sidhartha also serves as a Professor of Practice at the Manipal Centre for Innovation, Leadership, and Entrepreneurship, highlighting his passion for shaping future leaders in finance and strategy.

Mumbai, May 13, 2025: P. D. Hinduja Hospital & Medical Research Centre, in collaboration with the Hinduja Foundation, today expanded its groundbreaking Type 1 Diabetes Initiative (T1DI) by donating insulin pumps to 20 underprivileged children as part of its Insulin Pump Therapy Initiation Program. Presently, the management and maintenance of these pumps will be fully supported for a period of five years. In addition to this, the hospital offers full medical care for diabetes management at no cost to close to 400 children with type 1 diabetes.

Through Type 1 Diabetes Initiative, P. D. Hinduja Hospital and Hinduja Foundation have been at the forefront of a transformative healthcare initiative for children and young adults living with Type 1 Diabetes since 2019. Since its launch, the initiative has supported over 400 children and invested over INR 11 crore to create a strong, sustainable model of care. It has helped improve average HbA1c levels from 10.2% to 7-8%, reduced hospitalizations by 75%, and strengthened treatment adherence through regular counselling and life skills education.

Mr. Gautam Khanna, CEO, P. D. Hinduja Hospital & MRC, said, “Today’s event marks an important milestone in our ongoing efforts to assist underprivileged children and their families in managing Type 1 Diabetes. The Hinduja Foundation and P. D. Hinduja Hospital have worked tirelessly over the years to develop a comprehensive and sustainable model of care and research as part of the Type 1 Diabetes Initiative. We remain deeply committed to expanding equal access to quality healthcare and doing scientific research that will define the future of diabetes care in India and around the world. The quality of life of these kids and even their families has had a positive impact with this program. With this program we aim to contribute to therapy management, research and therapy cure solutions for Type 1 Diabetes.”

Dr. Phulrenu Chauhan, Head – Department of Endocrinology, P. D. Hinduja Hospital & MRC, said, “With the support of Hinduja Group and Hinduja Foundation, we are proud to donate insulin pumps to 20 children as part of our Insulin Pump Therapy Initiation Program. This is just one step in our broader Type 1 Diabetes Initiative, which has been providing comprehensive, free-of-cost care to about 400 children. With the insulin pumps, we are ensuring better blood sugar control, fewer complications, and a higher quality of life for these children, while the T1DI clinic continues to offer life-changing treatment, education, and ongoing support.”

Type 1 diabetes is a chronic, lifelong condition that necessitates intensive management. This includes four insulin injections, and 2-4 blood glucose checks per day, regular lab monitoring and consultations, and education in carbohydrate counting, insulin titration, and lifestyle modification. The high cost of insulin, syringes, blood glucose strips, and consultation fees makes it nearly impossible for patients from lower socioeconomic strata to effectively manage T1D. Many children suffer complications or early mortality due to lack of access to even basic care. To ensure access to quality and lifesaving treatment, the P. D. Hinduja Hospital and the Hinduja Foundation remain committed to cover the entire cost for these underprivileged children.

Dr. Ashish Mendhi, Program Director, Hinduja Foundation, underscored, “This initiative stands as a beacon of what targeted, compassionate, and evidence-based care can achieve, especially when directed toward vulnerable populations. In collaboration with P. D. Hinduja Hospital, today’s event underscores Hinduja Foundation’s commitment to continue expanding the program’s reach, advancing scientific research, and shaping dialogue on equitable and effective T1D care.”

The Type 1 Diabetes Initiative by P. D. Hinduja Hospital and the Hinduja Foundation is a pioneering, life-transforming program that serves as a model for accessible, sustainable, and evidence-based chronic disease care. With robust clinical outcomes, scientific contributions, and a commitment to equity, this program demonstrates what is possible when care and compassion meet scientific rigor.

New Delhi, May 8, 2025: Ujala Cygnus Group of Hospitals, North India’s largest NABH accredited healthcare providers, has announced a special Mother’s Day campaign dedicated to honouring the invaluable role of mothers and mothers-to-be. The initiative will be held on Saturday, 10th May (a day ahead of Mother’s Day on 11th May- Sunday), across more than 15 prominent Ujala Cygnus hospitals in 5 states, offering a host of complimentary and discounted services to ensure that every mother feels celebrated and cared for.

As part of the campaign, mothers and expecting mothers visiting Ujala Cygnus hospitals on May 10 will be entitled to a free gynecology consultation, a 50% discount on ultrasounds, and a 50% discount on any additional investigations recommended during the visit. The initiative aims to encourage women to prioritize their health while enjoying a warm and welcoming experience.

Commenting on the initiative, Mr. Probal Ghosal, Chairman, Director, and Co-Founder of Ujala Cygnus Healthcare Services, said: “The Mother figure is the defining figure in Indian families, and we at Ujala Cygnus recognise this; we see Mother’s Day as an opportunity to serve and empower her and encourage her to begin the healthcare transformation of the family starting with herself. Accessible healthcare can make a meaningful difference to families, but it is only possible if the mother in each house prioritizes her health first.”

Echoing this sentiment, Dr. Shuchin Bajaj, Founder Director, Ujala Cygnus Hospitals, added: “Too often women place their own health needs last while caring for their families. This Mother’s Day, we’re offering them a moment to focus on themselves, with access to essential gynecological  services and guidance. Whether it’s understanding the importance of balanced nutrition, safe exercise during pregnancy, or simply learning how to prevent common summer ailments, preventive healthcare is key. Our goal is to build awareness and make these conversations part of every woman’s journey to motherhood.”

Some of the key hospitals offering these benefits include Ujala Cygnus Kulwanti Hospital, Kanpur; Ujala Cygnus Central Hospital, Haldwani; Ujala Cygnus Rainbow Hospital, Agra; Ujala Cygnus Laxmi Hospital, Varanasi; Ujala Cygnus Sonia Hospital, Nangloi (New Delhi), alongside other participating hospitals in the network.

In addition to healthcare services, mothers visiting the hospitals on this special day will enjoy free transportation from designated city locations, as well as complimentary refreshments and a small gift as a token of appreciation.

Ujala Cygnus has always prioritized maternal healthcare and educating women on how to navigate their pregnancy journey in a better way by taking care of their mental and physical well-being. The hospital chain celebrates Mother’s Day every year with events and promotions, often emphasizing the importance of maternal health and safe childbirth.

Guwahati : When we think of liver problems, we often associate them with adults. But the truth is, liver conditions can affect children too—especially when they are inherited through family genes. These are called genetic liver disorders. Though they may sound worrying, understanding them early and getting the right help can make a big difference in your child’s health and future says Dr. Vikram Kumar, Principal Consultant, Paediatric Liver Transplantation, Gastroenterology & Hepatology, Max Hospital, Saket.

What Are Genetic Liver Disorders?

Genetic liver disorders are inherited conditions that affect how a child’s liver functions. They may disrupt the body’s ability to break down substances, produce bile, or remove toxins. Some of the most recognised disorders include Wilson’s disease, Alpha-1 Antitrypsin deficiency, and Glycogen storage diseases, Biliary Atresia.

Children affected by these disorders might not display symptoms right away. Some only experience signs as they grow—like persistent jaundice, swelling in the belly, fatigue, poor weight gain, or pale stools. In many cases, parents only discover the issue during routine check-ups or blood tests.

Early Detection Makes All the Difference

The liver is a silent worker. It performs hundreds of essential functions every day—but when it’s not working right, the effects can be serious. If not properly managed, several inherited liver conditions may progress to cirrhosis, liver failure, or require a liver transplant. That’s why early intervention is critical.

With timely diagnosis and expert care, children can be treated successfully—even before symptoms appear. And that brings hope.

Pediatric Liver Treatments That Give Children a Healthier Future

Thanks to advances in pediatric liver care, most genetic liver disorders can now be managed effectively through a combination of:

• Medications that remove toxic build-up or improve bile flow
• Custom diet plans tailored to the child’s condition
• Supplements containing essential vitamins and minerals that help promote healthy growth and support liver function
• Regular monitoring through tests and imaging
• In certain cases, a liver transplant may be recommended, providing a new chance at life for children with serious liver damage

These treatments are not one-size-fits-all—they are personalised. A team of pediatric liver experts will create a personalised treatment plan tailored to your child’s specific condition, age, and overall health.

What Can Parents Do?

If your child shows signs of liver trouble or if you have a family history of liver disease, talk to a pediatric liver expert. Don’t ignore symptoms like long-term jaundice, poor appetite, or unexplained tiredness. Early screening can be life-changing.

And remember: treatment doesn’t just aim to control the condition—it’s about helping your child live life to the fullest.

Expert Help Is Closer Than You Think

Parents often feel helpless when facing a child’s diagnosis. But with the right information and expert medical care, there’s every reason to feel hopeful. A timely diagnosis, personalised treatment plan, and regular follow-up can make all the difference in your child’s health journey.

In an initiative to bring together leading oncologists from across the country in the fight against Cancer, Max Institute of Cancer Care, Vaishali organized the biggest Oncology event in the region today- ONCO–CON 2025, on the theme “Close the Care Gap”. The two daylong conference witnessed the participation of over 700+ eminent oncologists, surgeons, radiologists, and clinicians from across India.

ONCO–CON is a high-impact platform for the country’s oncology experts to deliberate on breakthroughs in cancer diagnostics, precision treatment, and multidisciplinary disease management. The event featured focused sessions on Breast, Lung, Gynaecological, GI, Head & Neck, Uro-Oncology, Haematological, and Pediatric cancers, with live debates, case-based discussions, panel interactions, workshops, and poster presentations.

During the event Dr. Harit Chaturvedi, Chairman of Max Institute of Cancer Care said “There was a time when cancer was considered as the end of life for every person, but today we are here discussing the success stories of rare cases of cancer that were treated promptly and how advanced technology like Da Vinci Xi robotic procedures are providing new lease of life to several cancer patients. All of this was made possible due to the several rapid advancements in the field of medical science over the past few years and through this platform, we were able to bring together leading oncologists in this battle against cancer.”

ONCO–CON 2025 also featured focused discussions on various Disease Management Groups (DMGs), enabling multidisciplinary insights into complex cancer cases. A dedicated haematology workshop provided learning experience on current therapeutic strategies. The precision and benefits of the Da Vinci Xi Surgical Robot were demonstrated, while a medical quiz and poster presentation fostered academic engagement among young clinicians.

Dr. Gopal Sharma, Principal Director, Medical Oncology – Max Super Speciality Hospital, Vaishali stated, “ONCO–CON 2025 has served as a powerful reminder of what we can achieve when the oncology community & primary care physicians come together. The exchange of ideas, case studies, and new technologies at this forum equips us to deliver more personalized and effective cancer care. As clinicians, we often face complex challenges, and such platforms provide not just academic insight, but also inspiration and collaboration. At Max Institute of Cancer Care, Vaishali we remain committed to driving innovation and teamwork in our shared mission to close the care gap and improve patient outcomes.”

Dr. Gaurav Aggarwal, Executive Vice President & Zonal Head, Max Super Speciality Hospital, Vaishali & Lucknow, added, “We are extremely pleased with the accomplishment of ONCO–CON 2025. As the prevalence of Cancer is increasing every year, our healthcare system needs to come together and join hands in order to provide better patient outcomes to those suffering from cancer. This conference has helped us bring together some of the brightest minds in the field of Oncology from across the country and provide them with a unique experience and opportunity to discuss the latest advancements in the field.”

Max Institute of Cancer Care, Vaishali, reaffirmed its commitment to fostering platforms like ONCO–CON annually, aimed at advancing knowledge exchange, innovation, and collaborative progress in the ongoing battle against cancer. As the most advanced cancer centre in the region, the Institute continues to lead the way in introducing and discussing cutting-edge oncology treatments such as robotic surgery, advanced radiation techniques like EDGE 3.0, CAR-T cell therapy, immunotherapy, Tomo-therapy, and more.

Vijayawada, 3rd May, 2025: In critical health emergencies, when ventilators and medications fall short, advanced interventions like ECMO (Extracorporeal Membrane Oxygenation) become vital. Now, Manipal Hospital Vijayawada has introduced ECMO services, offering a powerful life-saving option and strengthening access to world-class critical care in the region.

What is ECMO?

ECMO is an advanced artificial heart-lung machine that temporarily takes over the function of the heart and lungs, allowing these organs to rest and heal. It is used for patients suffering from severe lung or heart failure, when conventional treatments no longer suffice.

Highlighting its importance, Dr. Srinivas Rao T, Consultant – ICU and Critical Care, said, “ECMO has proven to be a life-saving intervention for patients suffering from acute respiratory distress syndrome (ARDS), severe pneumonia, pulmonary embolism, and in critical cases following cardiac surgery. Looking ahead, ECMO is expected to play a crucial role in normothermic regional perfusion — a technique used to preserve organs prior to harvesting for organ transplantation. In this evolving field, Hybrid ECMO is emerging as a promising innovation, combining the benefits of various ECMO modalities to optimize organ preservation and support advanced critical care.”

How does ECMO work?

 Explaining its mechanism, Dr. V Dinesh Kumar Gontla, Consultant – Critical Care, shared, “ECMO has two major parts – the oxygenator and the pump. While the oxygenator emulates the lungs’ blood-purifying functions, the pump is responsible for the heart’s pumping action. With these dual functions, the ECMO acts either as ‘A bridge to recovery’ in patients recovering from acute respiratory or cardiac failure conditions, and ‘A bridge to transplant’ in patients with advanced respiratory or cardiac failure who are undergoing lung or heart transplant.”

There are two types of ECMO:

• VV-ECMO (Veno-Venous): Supports only the lungs, ideal for conditions like ARDS, severe pneumonia, or COVID-19 complications.
• VA-ECMO (Veno-Arterial): Supports both the heart and lungs, used in cardiac arrest, severe heart attacks, or major heart failures.

Precision and Expertise Required

While ECMO may sound simple, its execution is highly complex. Dr. Srinivas Rao emphasized the need for a skilled, multidisciplinary team comprising cardiac surgeons, intensivists, pulmonologists, cardiologists, perfusionists, and specially trained ICU nurses and technicians.

Manipal Hospital Vijayawada, with its state-of-the-art infrastructure and specialized team, is committed to providing this advanced critical care service, giving critically ill patients a stronger chance at survival and recovery.

BENGALURU, India ,2 May 2025: Remidio Innovative Solutions Pvt. Ltd., a leader in ophthalmic technology, has announced that it has received approval from the State FDA, Karnataka (CDSCO), the regulatory authority for medical devices, for its Medios HI (Humanizing Intelligence) Glaucoma AI and Medios HI AMD AI. This approval represents an important advancement in the use of artificial intelligence (AI) for early detection of glaucoma and age-related macular degeneration (AMD) in diverse healthcare settings.

Following the success of the CDSCO-approved Medios DR HI, AI for diabetic retinopathy, which has impacted nearly 2,50,000 patients in the past year, the newly approved AI solutions for glaucoma and AMD are also designed to function offline. This offline capability allows real-time analysis without relying on internet access, making it useful for providing eye care in remote and underserved areas with limited access to specialized ophthalmic diagnostics.

Medios HI Glaucoma AI exceeds conventional screening methods by analyzing optic nerve head and RNFL structures, generating heat map–based reports to detect early signs of referable glaucoma. This is vital in a country like India, which accounts for 12 million glaucoma patients, nearly one in eight globally. Yet over 90% of these cases remain undiagnosed, often leading to irreversible vision loss. Early detection using portable, AI-enabled tools can drastically change this trajectory.

The Medios HI AMD AI, detects early-stage age-related macular degeneration (AMD), a major cause of vision impairment among the elderly. With 2.1% of Indians over age 60 affected, amounting to nearly 6.7 million people at risk, this tool plays a crucial role in enabling timely referrals and preventive care by highlighting lesions with AI generated heat maps.

Medios HI Glaucoma and Medios HI AMD Al has been clinically validated across tertiary hospitals, eye institute and vision centres showcasing high level of sensitivity and specificity. With Medios HI on Remidio’s FOP NM 10, a single tap delivers results for screening AMD, Glaucoma, and DR in few seconds.  Three critical insights, one seamless experience.

Dr. R. Kim, Chief Medical Officer, Senior Medical Consultant, Retina & Vitreous Services Director, Aravind Eye Hospital, Madurai said “The Remidio fundus camera isn’t just an imaging device; it’s a portable gateway to early detection and prevention of vision-threatening conditions, bringing quality eye care closer to those who need it most” 

Dr Anand Sivaraman, CEO and Founding Director, Remidio said “The CDSCO‘s approval of our Medios HI Glaucoma AI and Medios HI AMD AI builds upon the foundation laid by our Medios HI DR AI, which was the first ophthalmic AI software to receive such approval in India. This achievement has enabled us to screen patients, particularly in underserved regions, bringing early detection and intervention to those who need it most. The success of Medios DR AI has demonstrated the transformative potential of AI in ophthalmology, and with these new approvals, we’re poised to further enhance eye care accessibility and precision across the country.“

Dr Divya Rao, Chief Medical Officer, Remidio added, “These CDSCO approvals are a testament to the clinical rigor and precision that underpins our AI solutions. Both the glaucoma and AMD algorithms have been evaluated through robust prospective studies and have demonstrated strong concordance with specialist diagnosis. What excites us is their ability to bring specialist-grade diagnostics to the primary care level, empowering early intervention, particularly in settings where access to ophthalmologists is limited.”

Sundeep Agarwal, Senior Vice President – Regulatory Affairs & Quality Assurance, Remidio, stated: “Securing CDSCO approvals for our Medios HI Glaucoma AI and AMD AI reflects Remidio’s deep commitment to regulatory rigor and patient safety. Navigating the complexities of AI regulation in India requires not just innovation, but robust documentation, compliance, and quality assurance at every stage. These approvals reaffirm our ability to deliver cutting-edge, regulatory-compliant solutions that meet the highest national standards, ensuring safe and scalable adoption in diverse healthcare settings.“

Remidio’s AI-powered solutions are integrated with its portable fundus imaging devices, facilitating seamless deployment in various clinical settings. The offline capability ensures that healthcare providers can conduct screenings without reliance on internet infrastructure, making it feasible to implement these solutions in rural and resource-limited environments.

With these approvals, Remidio continues to lead in the development of AI-driven ophthalmic diagnostics, aiming to bridge the gap in eye care delivery and contribute to the global effort in combating vision impairment.